JTC Employer Solutions Trustee Ltd Buys Shares of 75,500 NewAmsterdam Pharma Company N.V. $NAMS

JTC Employer Solutions Trustee Ltd bought a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in the fourth quarter, Holdings Channel reports. The fund bought 75,500 shares of the company’s stock, valued at approximately $2,649,000.

Other hedge funds have also made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the last quarter. Navalign LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $46,000. NBC Securities Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $86,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of NewAmsterdam Pharma by 26.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock valued at $193,000 after acquiring an additional 1,156 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NAMS. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Truist Financial started coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Finally, Guggenheim upped their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.00.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $35.42 on Friday. The business has a 50 day simple moving average of $33.25 and a 200-day simple moving average of $34.20. The firm has a market capitalization of $4.14 billion, a PE ratio of -19.79 and a beta of 0.02. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.95 and a 1 year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current year.

Insider Buying and Selling

In other news, Director Louis G. Lange sold 44,619 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the sale, the director directly owned 10,360 shares in the company, valued at $315,151.20. This represents a 81.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61. Following the completion of the transaction, the insider owned 69,302 shares of the company’s stock, valued at $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 881,512 shares of company stock valued at $28,350,236 over the last ninety days. 12.74% of the stock is currently owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.